BMRN241220P60000
- 1.10
- +0.30+37.50%
Biomarin Pharmaceutical Newsroom
Express News | Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research
Biomarin Pharmaceutical Analyst Ratings
Wolfe Research Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $95
Biomarin Pharmaceutical Insider Sold Shares Worth $350,324, According to a Recent SEC Filing
Biomarin Pharmaceutical To Present At UBS Global Healthcare Conference; Webcast At 2:00 PM ET
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options
Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN)
Is BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Recent Price Movement Underpinned By Its Weak Fundamentals?
Peering Into Biomarin Pharmaceutical's Recent Short Interest
CAMP4 Analyst Highlights Rare Disease Platform Potential
Wedbush Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $94
Express News | Biomarin Pharmaceutical Inc : Wedbush Assumes Coverage With Outperform Rating; Target Price $94
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $86
Oppenheimer Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical | 10-Q: Q3 2024 Earnings Report